Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Johns Hopkins University Baltimore-India Clinical Trials Unit